BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope ...

“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...

Intranasal (IN) delivery of medications is a relatively new area of interest in the field of transmucosal medication delivery, but is gaining popularity in the world of healthcare for several reasons.

The intranasal delivery method of Naloxone presents several benefits, such as ease of use and the elimination of the need for medical professionals during administration, making it more accessible ...

Kenox and Lactiga US have announced a strategic partnership for progressing new mucosal-targeted sIgA therapies development.

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...

In a recent publication in Cell, researchers from the National University of Singapore and collaborators have proposed using commensal bacteria in the nasal cavity as a delivery vector for precision ...

"Our proprietary T&T platform is designed to optimize drug delivery, and we believe it holds the potential to enhance intranasal Naloxone by offering higher bioavailability for increased drug ...

Conclusions: This study found intranasal administration of hydromorphone ... These data support further investigation of this single-dose delivery system for clinical use. The IN route potentially ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...

Polyrizon (PLRZ) announced that it has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived ...